Hyderabad researchers disarm drug-resistant fungus in new study

Indian Opinion DeskIndian Opinion DeskGovernance3 minutes ago1 Views

The Story in Brief

Researchers at CSIR-CCMB in Hyderabad have identified compounds that prevent the fungus Candida albicans from switching into its invasive filament form, a method that disarms the pathogen rather than killing it. The approach targets the sugar metabolism pathway glycolysis, blocking the shape change that allows the fungus to evade the immune system. Published in ACS Infectious Diseases, the study found that a lead compound increased the sensitivity of the fungus to existing antifungal drugs such as fluconazole and amphotericin B, and improved survival in preclinical mouse models.

Hyderabad researchers disarm drug-resistant fungus in new study

The research, led by Sriram Varahan in collaboration with BRIC-THSTI, highlights pyruvate kinase as a crucial regulator of the morphology switch. First author Dhrumi Shah said the findings show that disease-associated fungal behaviour can be targeted without stopping growth. The researchers noted that further studies are needed to evaluate the compounds' effectiveness and safety before any clinical application.

Indian Opinion Analysis

Both Telangana Today and The Hindu reported the CCMB study with near-identical wire-style coverage, making the same scientific claims about the disarming approach, pyruvate kinase, and the mouse-model survival gain. The only meaningful divergence is in the handling of a named source: The Hindu quotes first author Dhrumi Shah and lead investigator Sriram Varahan, adding a human voice to the findings, while Telangana Today offers no direct quotation. The same core factual sequence appears in both outlets, consistent with a shared press release origin. The uniform, straight-reporting treatment means no pro-government or critical leaning emerges, the analysis instead rests on the science itself. The study's central promise, targeting pathogen behaviour rather than viability, stands as the leading narrative, with subsequent safety and efficacy trials as the concrete next step the story leaves open.

Coverage: 2 sources, 2 neutral


Sources (2): telanganatoday.com (neutral report), thehindu.com (neutral report)

This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Methodology and corrections.

Ask their opinion on this story
They have read this article, our coverage, and the web.
AI simulations of historical figures. Responses are generated from the historical record, not authentic statements.

0 Votes: 0 Upvotes, 0 Downvotes (0 Points)

Share your opinion

Sign in to comment

Comments are open to readers with an Indian Opinion account. We email you a 6-digit code; there is no password.

Sign in to comment

Loading Next Post...
Search Trending
Ask their opinion
Loading

Signing-in 3 seconds...

Signing-up 3 seconds...

All fields are required.